New Bay Area building marks significant progress as part of $32 billion US investment projected to create $43 billion in economic value
Now integrates with Abbott’s instinct sensor and approved for type 2 diabetes
Phase 1 has a total reactor capacity of 440 kL with 63 reactors
It offers clear environmental benefits, lower emissions, reduced hazardous material use, and alignment with circular economy goals
Fortis will assume complete operational and financial control, allowing it to consolidate the hospital's performance within its network
With the addition of Phase II (~91 KL) in Q1 FY26, the combined capacity of the block now stands at ~200 KL
WIDAPLIK is the first and only FDA-approved triple combination medication for use as an initial therapy in patients likely to need multiple drugs to achieve blood pressure goals
LHP588 is an oral, brain-penetrant lysine-gingipain (Kgp) inhibitor designed to block the key virulence factor of P. gingivalis
The new lineup includes CereTom Elite, OmniTom Elite, OmniTom Elite PCD, and BodyTom 32/64
Subscribe To Our Newsletter & Stay Updated
